Drug intelligence / Profile preview

Atorvastatin + Clopidogrel

Development stage
Unknown
Lead developer
Pfizer
Modality
Drug Delivery Systems
Administration
Oral
01

Overview

Atorvastatin + clopidogrel is a combination medication that pairs two distinct drugs with complementary cardiovascular benefits. This combination brings together atorvastatin, a statin that lowers cholesterol levels, with clopidogrel, an antiplatelet agent that prevents blood clots. ## Mechanism and Uses This combination is primarily prescribed for individuals at high risk of cardiovascular events such as heart attacks and strokes. Atorvastatin works by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol production in the liver, which leads to lower LDL (bad cholesterol) levels and improved HDL (good cholesterol) levels[5]. Clopidogrel, on the other hand, inhibits platelet aggregation, reducing the risk of blood clot formation[5]. The combination is particularly valuable for: - Prevention of heart attacks and strokes - Post-angioplasty and stenting therapy - Management of high cholesterol alongside blood clot prevention ## Potential Interaction Concerns Interestingly, research has identified a potential interaction between these two medications. Several studies suggest that atorvastatin may reduce the effectiveness of clopidogrel[1][3][4]. This interaction appears to be dose-dependent, with higher doses of atorvastatin potentially causing greater reduction in clopidogrel's antiplatelet effects[7]. The mechanism behind this interaction involves the cytochrome P450 (CYP) enzyme system, particularly CYP3A4. Both medications are metabolized through this pathway, and atorvastatin may compete with clopidogrel for metabolism, potentially reducing clopidogrel's conversion to its active form[3][7]. A study of patients with peripheral artery disease found that those taking both medications showed significantly less platelet inhibition compared to those on clopidogrel alone[3]. However, clinical significance of this interaction remains somewhat controversial, with some larger studies showing no significant difference in clinical outcomes[4]. ## Available Formulations The combination is available under various brand names including: - Aztolet (Sun Pharmaceutical Industries) - Atorfit CV (Ajanta Pharma) - Clopitorva (Zydus Cadila) - Atormac CV (Macleods Pharmaceuticals) - Clavilip (Intas Pharmaceuticals) - Storvas CV (Sun Pharmaceutical) - Avas CV (Micro Labs) - Atorlip CV (Cipla) - Astin CV (Micro Labs) - Lipicure CV (Intas Pharmaceuticals)[2] ## Side Effects Common side effects include: - Diarrhea - Headache - Muscle pain - Abdominal pain - Joint pain - Nosebleeds - Sleep disturbance - Dyspepsia[2] Due to the potential interaction concerns, healthcare providers should carefully consider the benefits and risks when prescribing this combination, particularly at higher atorvastatin doses.

Brand names
AztoletAtorfit CVClopitorvaAtormac CVClavilipStorvas CVAvas CVAtorlip CVAstin CVLipicure CV
Other names
clopidogrel bisulfateatorvastatin calciumSR25990CSR-25990CSR 25990CCI-981CI981CI 981
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)P2Y12 (Purinergic P2Y12 receptor)

Beyond the preview

Go deeper on Atorvastatin + Clopidogrel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atorvastatin + Clopidogrel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call